John P. Leonard, MD - Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL - a podcast by PVI, PeerView Institute for Medical Education
from 2020-02-26T18:00
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
Further episodes of PeerView Immunology
Further podcasts by PVI, PeerView Institute for Medical Education